Viral Vector Manufacturing Market to See 17.5% Annual Growth Through 2023

October 18, 2018

WELLESLEY, Mass., October 18, 2018–The increasing prevalence of genetic disorders and chronic diseases, along with a rising number of clinical trials in viral vectors, is helping to boost growth of the viral vector manufacturing market, according to a report by BCC Research.

The industry expects to see a compound annual growth rate (CAGR) of 17.5% through 2022, when it could be worth nearly $51.2 million, according to the report Global Viral Vector Manufacturing Markets and Technologies Through 2022.

Major players in the market include Advanced Bioscience Laboratories, Batavia Biosciences, Cell and Gene Therapy Catapult, GeneDetect, Lonza (LZAGF), Merck Millipore, Paragon Bioservices, Sanofi (SNY), Spark Therapeutics (ONCE) and Valneva (VNVLF).  

Research Highlights

  • Pox virus vaccines will lead the market by type, with an estimated 2022 value of $15.1 million, followed by adenoviral vectors at $10.8 million and adeno-associated viral vectors at $8.3 million.
  • The pox virus vaccine will see the strongest growth in North America, with a CAGR through 2022 of $5.8 million, followed by Europe at 18.0% and the Asia-Pacific region at 17.6%.
  • Veterinary applications will lead the market by size, with an estimated 2022 value of $43.0 million, though human applications will lead by growth, with a CAGR through the period of 18.2%.

“Viral vector vaccines are radical new approach … that use live viruses to carry DNA into human cells,” said BCC Research analyst and report author Vijay Laxmi. “Viral vectors are genetically modified virus platforms such as lentivirus vectors, retrovirus vectors, adeno-associated virus vector, cytomegalovirus vectors and others. In the vaccine manufacturing context, viral vectors are considered an ideal candidate for the vaccine manufacturing for both humans and animals.”

Future May Include Vaccines for HIV/AIDS 

Viral vectors are considered potential candidates for the development of vaccines for HIV/AIDS, for which no effective prophylactic vaccines are currently available, the report’s author added. Viral vectors have caught significant attention among those working to develop HIV vaccines. Over 100 clinical trials concerning viral vector-based vaccines (adeno, adeno-associated, alphavirus, etc.) against HIV have been listed on the International AIDS Vaccine Initiative as of April 2018.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Global Viral Vector Manufacturing Markets and Technologies Through 2022( PHM172A )
Publish Date: Oct 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.